CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Baird 2018 Global Healthcare Conference. The presentation will take place on Thursday, September 6 th , 2018 at 9:40AM ET at the Intercontinental New York Barclay Hotel, in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website,  investors.surfaceoncology.com . 

ABOUT SURFACE ONCOLOGY Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit  www.surfaceoncology.com .

Contacts: Seth Lewis slewis@surfaceoncology.com 617-655-5031

Ann Stanesa, Ten Bridge Communications Ann@tenbridgecommunications.com 617-230-0347